Corient IA LLC Invests $319,000 in Edwards Lifesciences Corporation $EW

Key Points

• Corient IA LLC acquired **4,400 shares** of Edwards Lifesciences Corporation, valued at approximately **$319,000**, during the first quarter.
• Edwards Lifesciences reported **$0.67 EPS** for the last quarter, surpassing analysts' expectations, with revenue reaching **$1.53 billion**—an **11.9% year-over-year increase**.
• **79.46%** of Edwards Lifesciences' stock is held by institutional investors, with several hedge funds increasing their stakes in the company recently.

Corient IA LLC bought a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 4,400 shares of the medical research company's stock, valued at approximately $319,000.

Several other institutional investors have also made changes to their positions in the company. Prosperity Consulting Group LLC increased its position in shares of Edwards Lifesciences by 3.6% in the fourth quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after acquiring an additional 134 shares in the last quarter. Arlington Trust Co LLC increased its position in shares of Edwards Lifesciences by 1.2% in the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock worth $804,000 after acquiring an additional 135 shares in the last quarter. Valeo Financial Advisors LLC increased its position in shares of Edwards Lifesciences by 2.8% in the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock worth $372,000 after acquiring an additional 142 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Edwards Lifesciences by 9.3% in the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock worth $123,000 after acquiring an additional 145 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after acquiring an additional 145 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 0.7%

EW stock traded up $0.5950 during trading hours on Friday, hitting $81.7550. The company's stock had a trading volume of 3,076,141 shares, compared to its average volume of 4,824,093. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $48.00 billion, a PE ratio of 11.76, a price-to-earnings-growth ratio of 3.92 and a beta of 1.08. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00. The stock has a 50 day moving average price of $77.58 and a two-hundred day moving average price of $74.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company's stock, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,584 shares of company stock valued at $1,897,762 over the last ninety days. Corporate insiders own 1.29% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on EW. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Robert W. Baird boosted their price objective on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a research report on Friday, July 25th. Evercore ISI boosted their price objective on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research report on Friday, July 25th. Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a research report on Friday, July 25th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $85.90.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.